EP1623046A4 - Compositions et procedes pour traiter le syndrome respiratoire aigu severe - Google Patents
Compositions et procedes pour traiter le syndrome respiratoire aigu severeInfo
- Publication number
- EP1623046A4 EP1623046A4 EP04809344A EP04809344A EP1623046A4 EP 1623046 A4 EP1623046 A4 EP 1623046A4 EP 04809344 A EP04809344 A EP 04809344A EP 04809344 A EP04809344 A EP 04809344A EP 1623046 A4 EP1623046 A4 EP 1623046A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- sars
- treatment
- methods
- acute respiratory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 title 1
- 241000315672 SARS coronavirus Species 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102100037399 Alanine-tRNA ligase, cytoplasmic Human genes 0.000 abstract 1
- 101000879354 Homo sapiens Alanine-tRNA ligase, cytoplasmic Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46642603P | 2003-04-28 | 2003-04-28 | |
US46777003P | 2003-04-30 | 2003-04-30 | |
US46856203P | 2003-05-06 | 2003-05-06 | |
US46862703P | 2003-05-06 | 2003-05-06 | |
US47763703P | 2003-06-10 | 2003-06-10 | |
US48357903P | 2003-06-27 | 2003-06-27 | |
US10/831,901 US7339051B2 (en) | 2003-04-28 | 2004-04-26 | Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) |
PCT/US2004/013050 WO2005023083A2 (fr) | 2003-04-28 | 2004-04-27 | Compositions et procedes pour traiter le syndrome respiratoire aigu severe |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1623046A2 EP1623046A2 (fr) | 2006-02-08 |
EP1623046A4 true EP1623046A4 (fr) | 2007-02-21 |
Family
ID=34682459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04809344A Withdrawn EP1623046A4 (fr) | 2003-04-28 | 2004-04-27 | Compositions et procedes pour traiter le syndrome respiratoire aigu severe |
Country Status (4)
Country | Link |
---|---|
US (1) | US7339051B2 (fr) |
EP (1) | EP1623046A4 (fr) |
CN (1) | CN1780922A (fr) |
WO (1) | WO2005023083A2 (fr) |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090298914A1 (en) * | 2003-04-15 | 2009-12-03 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (SARS) Virus Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US7527926B2 (en) * | 2003-04-21 | 2009-05-05 | Genome Institute Of Singapore | Oligonucleotides, reagents and amplification methods for detecting severe acute respiratory syndrome coronavirus |
US20050137154A1 (en) * | 2003-05-16 | 2005-06-23 | Hemispherx Biopharma | Treating server acute respiratory syndrome |
US20060035859A1 (en) * | 2003-05-16 | 2006-02-16 | Hemispherx Biopharma | Treating severe and acute viral infections |
US7361747B2 (en) * | 2003-05-22 | 2008-04-22 | The University Of Hong Kong | Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus |
CA2538086A1 (fr) * | 2003-09-12 | 2005-03-24 | Becton, Dickinson And Company | Epreuve biologique de depistage du coronavirus du sras par amplification et detection de la sequence arn de la nucleocapside |
US7480382B2 (en) * | 2003-09-30 | 2009-01-20 | Microsoft Corporation | Image file container |
US7439032B2 (en) | 2003-10-21 | 2008-10-21 | New York University | Methods to identify compounds useful for tumor sensitization to DNA damage |
KR100994568B1 (ko) * | 2003-12-12 | 2010-11-15 | 삼성전자주식회사 | 사스 코로나바이러스 검출용 프라이머, 그를 이용한 사스코로나바이러스 검출 방법 및 키트 |
US20070248949A1 (en) * | 2003-12-17 | 2007-10-25 | Agency For Science, Technology And Research | Sensitive and Specific Test to Detect Sars Coronavirus |
US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
EP1915622A2 (fr) * | 2005-07-29 | 2008-04-30 | Oncotherapy Science, Inc. | Criblage et methode therapeutique anti-nsclc ciblant le complexe cda1-kntc2 |
CN101437933B (zh) * | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | 作为药物靶标的天然反义和非编码的rna转录物 |
CN101437534A (zh) * | 2006-03-08 | 2009-05-20 | 半球生物制药公司 | 口服干扰素的广谱免疫和抗病毒基因调节作用 |
US8075877B2 (en) | 2006-03-08 | 2011-12-13 | Hemispherx Biopharma | Broad spectrum immune and antiviral gene modulation by oral interferon |
KR101007469B1 (ko) | 2006-12-22 | 2011-01-12 | 성균관대학교산학협력단 | 사스 코로나 바이러스의 rna 유사매듭구조에 결합하여 리보솜 틀 이동을 억제하는 호모피페라진계 화합물 |
US9598724B2 (en) | 2007-06-01 | 2017-03-21 | Ibis Biosciences, Inc. | Methods and compositions for multiple displacement amplification of nucleic acids |
MX2010000655A (es) * | 2007-07-17 | 2010-04-30 | Universit Laval | Secuencias de acido nucleico para la amplificacion y deteccion de virus respiratorios. |
MX339820B (es) * | 2008-10-03 | 2016-06-13 | Curna Inc | Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1. |
CN102341498B (zh) | 2008-12-04 | 2017-12-19 | 库尔纳公司 | 通过抑制血管内皮生长因子(vegf)的天然反义转录子治疗vegf相关的疾病 |
KR101866152B1 (ko) | 2008-12-04 | 2018-06-08 | 큐알엔에이, 인크. | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
US8921329B2 (en) * | 2008-12-04 | 2014-12-30 | Curna, Inc. | Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO |
EP2396038B1 (fr) | 2009-02-12 | 2015-10-21 | CuRNA, Inc. | Traitement des maladies associées au facteur neurotrophique dérivé du cerveau (bdnf) par inhibition du produit antisens naturel de la transcription en bdnf |
JP6116242B2 (ja) | 2009-03-16 | 2017-04-19 | クルナ・インコーポレーテッド | 核因子(赤血球由来2)様2(nrf2)に対する天然アンチセンス転写物の抑制によるnrf2関連疾患の治療 |
WO2010107740A2 (fr) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Traitement des maladies associées à l'homologue du delta-like 1 (dlk1) par inhibition du transcrit antisens naturel de dlk1 |
WO2010114842A1 (fr) | 2009-03-30 | 2010-10-07 | Ibis Biosciences, Inc. | Systèmes, dispositifs et procédés de détection d'agent biologique |
JP6250930B2 (ja) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | トリステトラプロリン(ttp)に対する天然アンチセンス転写物の抑制によるttp関連疾患の治療 |
EP2427553A4 (fr) | 2009-05-06 | 2012-11-07 | Opko Curna Llc | Traitement de maladies associées aux gènes du métabolisme et du transport des lipides par inhibition de transcrit antisens naturel d'un gène du métabolisme et du transport des lipides |
JP5931720B2 (ja) | 2009-05-08 | 2016-06-08 | クルナ・インコーポレーテッド | Dmdファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療 |
CN102575251B (zh) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | 通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病 |
CA2762987A1 (fr) | 2009-05-22 | 2010-11-25 | Joseph Collard | Traitement des maladies liees au facteur de transcription e3 (tfe3) et au substrat recepteur d'insuline 2 (irs2) par inhibition du transcript antisens naturel du tfe3 |
WO2010138806A2 (fr) | 2009-05-28 | 2010-12-02 | Curna, Inc. | Traitement de maladies associées à un gène antiviral grâce à l'inhibition d'un produit de transcription antisens naturel d'un gène antiviral |
WO2010148065A2 (fr) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Traitement de maladies liées à la paraoxonase 1 (pon1) par inhibition d'un produit de transcription antisens naturel à pon1 |
CA2765700C (fr) | 2009-06-16 | 2021-01-05 | Opko Curna, Llc | Traitement de maladies liees au gene du collagene par inhibition d'un produit de transcription antisens naturel a un gene du collagene |
EP2446036B1 (fr) | 2009-06-24 | 2017-03-01 | CuRNA, Inc. | Traitement de maladies associées au récepteur de facteur nécrosant des tumeurs 2 (tnfr2) par inhibition de la transcription antisens naturelle de tnfr2 |
CN102482672B (zh) | 2009-06-26 | 2016-11-09 | 库尔纳公司 | 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病 |
WO2011011700A2 (fr) * | 2009-07-24 | 2011-01-27 | Curna, Inc. | Traitement des maladies associées à une sirtuine (sirt) par inhibition du produit de transcription anti-sens naturel chez une sirtuine (sirt) |
WO2011014811A1 (fr) | 2009-07-31 | 2011-02-03 | Ibis Biosciences, Inc. | Amorces de capture et supports solides liés à une séquence de capture pour tests diagnostiques moléculaires |
KR101802536B1 (ko) | 2009-08-05 | 2017-11-28 | 큐알엔에이, 인크. | 인슐린 유전자 (ins)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ins) 관련된 질환의 치료 |
ES2599986T3 (es) | 2009-08-11 | 2017-02-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ) |
US8614090B2 (en) * | 2009-08-19 | 2013-12-24 | Blood Systems, Inc. | Astrovirus species |
JP5943836B2 (ja) | 2009-08-21 | 2016-07-05 | カッパーアールエヌエー,インコーポレイテッド | ‘hsp70相互作用タンパク質c末端’(chip)に対する天然アンチセンス転写産物の阻害によるchip関連疾患の治療 |
WO2011031482A2 (fr) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Traitement de maladies associées à la protéine d'activation de gtpase contenant un motif iq (iqgap), par inhibition d'un transcrit antisens naturel de iqgap |
NO2480669T3 (fr) | 2009-09-25 | 2018-04-07 | ||
US9890408B2 (en) | 2009-10-15 | 2018-02-13 | Ibis Biosciences, Inc. | Multiple displacement amplification |
US9173895B2 (en) | 2009-12-16 | 2015-11-03 | Curna, Inc. | Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1 |
CN102869776B (zh) | 2009-12-23 | 2017-06-23 | 库尔纳公司 | 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病 |
EP2515947B1 (fr) | 2009-12-23 | 2021-10-06 | CuRNA, Inc. | Traitement de maladies associées à la protéine ucp2 (uncoupling protein) par inhibition du produit de transcription antisens naturel en ucp2 |
CA2785173A1 (fr) | 2009-12-29 | 2011-07-28 | Curna, Inc. | Traitement de maladies liees au facteur respiratoire nucleaire 1 (nrf1) par l'inhibition du produit de transcription antisens naturel de nrf1 |
US8962585B2 (en) | 2009-12-29 | 2015-02-24 | Curna, Inc. | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
RU2616283C2 (ru) | 2009-12-31 | 2017-04-13 | Курна, Инк. | Лечение заболеваний, связанных с субстратом рецептора инсулина 2 (irs2), путем ингибирования природного антисмыслового транскрипта к irs2 |
ES2664605T3 (es) | 2010-01-04 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor 8 regulador del interferón (irf8) mediante inhibición del transcrito antisentido natural al gen irf8 |
RU2612161C2 (ru) | 2010-01-06 | 2017-03-02 | Курна, Инк. | Лечение заболеваний, связанных с геном развития поджелудочной железы, путем ингибирования природного антисмыслового транскрипта к гену развития поджелудочной железы |
KR101854926B1 (ko) | 2010-01-11 | 2018-05-04 | 큐알엔에이, 인크. | 성 호르몬 결합 글로불린 (shbg)에 대한 자연 안티센스 전사체의 저해에 의한 성 호르몬 결합 글로불린 (shbg) 관련된 질환의 치료 |
EP2529015B1 (fr) | 2010-01-25 | 2017-11-15 | CuRNA, Inc. | Traitement de maladies liées à la rnase h1 par l'inhibition du produit de transcription naturel antisens de la rnase h1 |
RU2608496C2 (ru) | 2010-02-22 | 2017-01-18 | Курна, Инк. | Лечение заболеваний, связанных с пирролин-5 карбоксилатредуктазой 1(pycr1), путем ингибирования природного антисмыслового транскрипта к pycr1 |
EP2545183B1 (fr) | 2010-03-10 | 2017-04-19 | Ibis Biosciences, Inc. | Production d'acide nucléique circulaire monocaténaire |
TWI600759B (zh) | 2010-04-02 | 2017-10-01 | 可娜公司 | 藉由抑制群落刺激因子3(csf3)之天然反義轉錄物以治療csf3相關疾病 |
US9068017B2 (en) | 2010-04-08 | 2015-06-30 | Ibis Biosciences, Inc. | Compositions and methods for inhibiting terminal transferase activity |
RU2610661C2 (ru) | 2010-04-09 | 2017-02-14 | Курна, Инк. | Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21 |
KR20130101442A (ko) | 2010-05-03 | 2013-09-13 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료 |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
ES2664572T3 (es) | 2010-05-26 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el homólogo atonal 1 (ATOH1) mediante inhibición del transcrito antisentido natural a ATOH1 |
US8980858B2 (en) | 2010-05-26 | 2015-03-17 | Curna, Inc. | Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA |
CA2803882C (fr) | 2010-06-23 | 2022-10-18 | Opko Curna, Llc | Traitement de maladies liees a la sous-unite alpha du canal sodique voltage-dependant (scna) par inhibition du produit de transcription naturel antisens a la scna |
JP5998131B2 (ja) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー,インコーポレイテッド | Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療 |
WO2012021291A2 (fr) * | 2010-08-09 | 2012-02-16 | University Of Maryland, Baltimore | Procédés de traitement des troubles pulmonaires obstructifs en utilisant des substances sapides amères |
KR101886457B1 (ko) | 2010-10-06 | 2018-08-07 | 큐알엔에이, 인크. | 시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료 |
CN103180445B (zh) | 2010-10-22 | 2018-02-16 | 库尔纳公司 | 通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病 |
US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
CA2818824A1 (fr) | 2010-11-23 | 2012-05-31 | Joseph Collard | Traitement de maladies associees a nanog par l'inhibition d'un transcript antisens naturel de nanog |
KR102043422B1 (ko) | 2011-06-09 | 2019-11-11 | 큐알엔에이, 인크. | 프라탁신 (fxn)에 대한 자연 안티센스 전사체의 저해에 의한 프라탁신 (fxn) 관련된 질환의 치료 |
CN108272782B (zh) | 2011-09-06 | 2021-04-23 | 库尔纳公司 | 小分子在制备治疗Dravet综合征或全面性癫痫伴热性惊厥附加症的药物中的用途 |
EP3170831A1 (fr) | 2011-09-06 | 2017-05-24 | Ibis Biosciences, Inc. | Procédés de préparation d'échantillons |
US9970061B2 (en) | 2011-12-27 | 2018-05-15 | Ibis Biosciences, Inc. | Bioagent detection oligonucleotides |
CN104583405A (zh) | 2012-03-15 | 2015-04-29 | 科纳公司 | 通过抑制脑源神经营养因子(bdnf)的天然反义转录物治疗bdnf相关疾病 |
WO2013142514A1 (fr) * | 2012-03-19 | 2013-09-26 | Isis Pharmaceuticals, Inc. | Procédés et compositions destinés à la modulation de l'expression de l'alpha-1-antitrypsine |
WO2014039916A1 (fr) * | 2012-09-06 | 2014-03-13 | The University Of Chicago | Polynucléotides antisens destinés à induire un saut d'exon et méthodes de traitement de dystrophies |
US20150241319A1 (en) | 2012-09-26 | 2015-08-27 | Thomas N. Chiesl | Swab interface for a microfluidic device |
US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
WO2014186874A1 (fr) | 2013-05-23 | 2014-11-27 | Yyz Pharmatech, Inc. | Procédés et compositions pour analyse spectrométrique de masse par hybridation et immuno liée à des enzymes |
WO2015143245A1 (fr) | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Méthodes pour moduler l'expression de l'ataxine 2 |
EP3119888B1 (fr) | 2014-03-19 | 2021-07-28 | Ionis Pharmaceuticals, Inc. | Compositions permettant de moduler l'expression de l'ataxine 2 |
CN104651379A (zh) * | 2015-02-05 | 2015-05-27 | 四川农业大学 | 一种重组猪流行性腹泻病毒n蛋白及其制备方法 |
PL3283500T3 (pl) | 2015-04-08 | 2021-05-31 | The University Of Chicago | Kompozycje i sposoby korygowania dystrofii mięśniowej obręczowo-kończynowej typu 2c z użyciem pominięcia egzonu |
US11661602B2 (en) * | 2018-03-02 | 2023-05-30 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Inhibition of polyomavirus replication |
MX2021000922A (es) | 2018-07-25 | 2021-03-31 | Ionis Pharmaceuticals Inc | Compuestos y metodos para reducir la expresion de la atxn2. |
US12006500B2 (en) * | 2020-01-23 | 2024-06-11 | Sirnaomics, Inc. | Composition and methods of RNAi prophylactics and therapeutics for treatment of severe acute respiratory infection caused by 2019 novel coronavirus (2019-nCoV) |
IL295112A (en) * | 2020-01-28 | 2022-09-01 | Codagenix Inc | Suboptimal polynucleotides and 2-cov-sars viruses and their uses |
US20230130878A1 (en) * | 2020-03-13 | 2023-04-27 | The Translational Genomics Research Institute | Methods and kits for the detection of sars-cov-2 |
WO2021188906A1 (fr) * | 2020-03-19 | 2021-09-23 | Nature's Toolbox, Inc. | Nouveau vaccin multivalent covid-19 à base d'arnm et ses procédés de production mis à l'échelle |
WO2021188931A1 (fr) * | 2020-03-20 | 2021-09-23 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions anti-coronavirus et méthodes d'utilisation de ces compositions |
US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
US11851702B2 (en) | 2020-03-23 | 2023-12-26 | The Broad Institute, Inc. | Rapid diagnostics |
JP2023518983A (ja) * | 2020-03-26 | 2023-05-09 | イオニアン・テクノロジーズ・エル・エル・シー | コロナウイルス感染症2019(covid-19)を検出するためのアッセイ |
TW202204615A (zh) | 2020-03-26 | 2022-02-01 | 美商阿尼拉製藥公司 | 冠狀病毒iRNA組成物及其使用方法 |
CN111320541B (zh) * | 2020-03-26 | 2023-05-26 | 四川大学华西医院 | 一种防治病毒疾病的化合物及其应用 |
US11149320B1 (en) * | 2020-03-31 | 2021-10-19 | Diasorin S.P.A. | Assays for the detection of SARS-CoV-2 |
WO2021207641A1 (fr) * | 2020-04-10 | 2021-10-14 | Aligos Therapeutics, Inc. | Molécules d'oligonucléotide antisens (aso) et leurs utilisations pour des maladies à coronavirus |
EP4133080A1 (fr) * | 2020-04-10 | 2023-02-15 | Aligos Therapeutics, Inc. | Molécules d'acide nucléique interférent court (sina) et leurs utilisations pour les maladies à coronavirus |
US20220000904A1 (en) * | 2020-04-29 | 2022-01-06 | Meharry Medical College | Antiviral agents for treatment of coronaviruses |
US20230203490A1 (en) * | 2020-05-07 | 2023-06-29 | Eleven Therapeutics Ltd. | Utilizing rna interference against sars-cov-2 |
EP4149623A1 (fr) * | 2020-05-15 | 2023-03-22 | Howard University | Compositions et méthodes de traitement et de détection d'une infection à coronavirus |
WO2021236763A2 (fr) * | 2020-05-20 | 2021-11-25 | Nitto Denko Corporation | Arn à double brin (arndb) dirigé contre des protéines de coronavirus |
WO2021236987A2 (fr) * | 2020-05-20 | 2021-11-25 | The Administrators Of The Tulane Educational Fund | Dosage à base de crispr pour détecter des pathogènes dans des échantillons |
JP2023533124A (ja) * | 2020-05-22 | 2023-08-02 | バイオニア コーポレーション | 二本鎖オリゴヌクレオチド及びこれを含むコロナウイルス感染症-19(covid-19)治療用組成物 |
EP4158028A2 (fr) * | 2020-05-28 | 2023-04-05 | University Of Massachusetts | Oligonucléotides pour la modulation de sars-cov-2 |
WO2021255151A1 (fr) * | 2020-06-17 | 2021-12-23 | 3A-Diagnostics Gmbh | Procédé de détection de la présence d'acide nucléique de coronavirus |
EP3929310A1 (fr) * | 2020-06-26 | 2021-12-29 | FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. | Procédés et moyens pour la détection d'acide nucléique du coronavirus |
KR102272800B1 (ko) * | 2020-06-30 | 2021-07-05 | 국방과학연구소 | 코로나바이러스 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스 감염증-19 예방 및 치료용 조성물 |
EP4192982A2 (fr) * | 2020-08-06 | 2023-06-14 | F. Hoffmann-La Roche AG | Compositions et procédés pour détecter le coronavirus 2 du syndrome respiratoire aigu sévère (sars-2), de la grippe a et de la grippe b |
CN111893217A (zh) * | 2020-08-18 | 2020-11-06 | 上海派森诺生物科技股份有限公司 | 一种新型冠状病毒组合物及其试剂盒及其检测方法 |
WO2022056117A1 (fr) * | 2020-09-10 | 2022-03-17 | Avidity Biosciences, Inc. | Compositions d'acide nucléique-polypeptide et leurs utilisations |
US20220090082A1 (en) * | 2020-09-11 | 2022-03-24 | Children's National Medical Center | Gapmer antisense oligonucleotides targeting sars-cov-2 for treating covid 19 |
WO2022087600A1 (fr) * | 2020-10-20 | 2022-04-28 | Duquesne University Of The Holy Spirit | Interactions de micro-arn en tant que cibles thérapeutiques pour la covid-19 et d'autres infections virales |
CN112472791A (zh) * | 2020-11-16 | 2021-03-12 | 复旦大学 | CsA脂质体在制备抗SARS-CoV-2药物中的应用 |
EP4008785A1 (fr) * | 2020-12-03 | 2022-06-08 | Justus-Liebig-Universität Gießen | Acides nucléiques circulaires et leurs utilisations pour interférer avec l'expression de génome et la prolifération des coronavirus |
IL307478A (en) * | 2021-04-09 | 2023-12-01 | Univ Emory | Thionucleosides as antiviral agents |
TW202340471A (zh) * | 2022-02-02 | 2023-10-16 | 美商愛羅海德製藥公司 | 用於抑制冠狀病毒(CoV)病毒基因體之RNAi藥劑、其組合物及使用方法 |
AR128558A1 (es) * | 2022-02-21 | 2024-05-22 | Hoffmann La Roche | Oligonucleótido antisentido |
WO2024059910A1 (fr) * | 2022-09-21 | 2024-03-28 | Newsouth Innovations Pty Limited | Agent thérapeutique siarn antiviral contre le sars-cov-2 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1458281A (zh) * | 2003-06-18 | 2003-11-26 | 天津环球中加生物科技有限公司 | 严重急性呼吸道综合症病原冠状病毒rna干扰制剂 |
WO2004092383A2 (fr) * | 2003-04-15 | 2004-10-28 | Sirna Therapeutics, Inc. | Inhibition par interference d'arn de l'expression genetique virale du syndrome respiratoire aigu severe au moyen d'acide nucleique d'interference court |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
DE69515652D1 (de) | 1994-03-30 | 2000-04-20 | Univ Montreal Montreal | Verwendung von dna oligomeren zur hemmung von hiv durch reduktion ribosomaler leserasterverschichtung |
US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US6180353B1 (en) * | 2000-01-24 | 2001-01-30 | Isis Pharmaceuticals Inc. | Antisense modulation of daxx expression |
-
2004
- 2004-04-26 US US10/831,901 patent/US7339051B2/en not_active Expired - Fee Related
- 2004-04-27 EP EP04809344A patent/EP1623046A4/fr not_active Withdrawn
- 2004-04-27 CN CNA2004800114115A patent/CN1780922A/zh active Pending
- 2004-04-27 WO PCT/US2004/013050 patent/WO2005023083A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004092383A2 (fr) * | 2003-04-15 | 2004-10-28 | Sirna Therapeutics, Inc. | Inhibition par interference d'arn de l'expression genetique virale du syndrome respiratoire aigu severe au moyen d'acide nucleique d'interference court |
CN1458281A (zh) * | 2003-06-18 | 2003-11-26 | 天津环球中加生物科技有限公司 | 严重急性呼吸道综合症病原冠状病毒rna干扰制剂 |
Non-Patent Citations (6)
Title |
---|
ABDOU S ET AL: "Beta-cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence", 1997, ARCHIVES OF VIROLOGY, VOL. 142, NR. 8, PAGE(S) 1585-1602, ISSN: 0304-8608, XP002397673 * |
DROSTEN C ET AL: "IDENTIFICATION OF A NOVEL CORONAVIRUS IN PATIENTS WITH SEVERE ACUTE RESPIRATORY SYNDROME", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 348, no. 20, 10 April 2003 (2003-04-10), pages 1967 - 1976, XP001182527, ISSN: 1533-4406 * |
KRISTEN PHILIPKOSKI: "Stopping SARS: A search for drugs.", WIRED NEWS, 28 April 2003 (2003-04-28), XP002397623, Retrieved from the Internet <URL:http://wired.com/news/medtech/1,58635-0.html> [retrieved on 20060904] * |
KSIAZEK T G ET AL: "A novel coronavirus associated with severe acute respiratory syndrome", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 348, no. 20, 10 April 2003 (2003-04-10), pages 1953 - 1966, XP002276003, ISSN: 1533-4406 * |
MARRA M A ET AL: "The genome sequence of the SARS-associated coronavirus", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399 - 1404, XP002269483, ISSN: 0036-8075 * |
ROTA P A ET AL: "Characterization of a novel coronavirus associated with severe acute respiratory syndrome", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1394 - 1399, XP002269482, ISSN: 0036-8075 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005023083A2 (fr) | 2005-03-17 |
EP1623046A2 (fr) | 2006-02-08 |
US7339051B2 (en) | 2008-03-04 |
WO2005023083A3 (fr) | 2005-06-23 |
US20050100885A1 (en) | 2005-05-12 |
CN1780922A (zh) | 2006-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005023083A3 (fr) | Compositions et procedes pour traiter le syndrome respiratoire aigu severe | |
WO2006035237A3 (fr) | Procedes et compositions lies a la maladie d'alzheimer | |
WO2005067546A3 (fr) | Derives et analogues de pyrrolopyrimidine et utilisation de ceux-ci dans le traitement a la prevention de maladies | |
WO2006096439A3 (fr) | Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees | |
MX2007004882A (es) | Derivados de xantina con actividad de receptor de hm74a. | |
TW200633992A (en) | Biaryloxymethylarenecarboxylic acids | |
WO2005063734A3 (fr) | Thiophenes substitues | |
WO2002047668A3 (fr) | Nouvelles compositions medicamenteuses a base d'anticholinergiques et de ciclesonide | |
WO2004043341A3 (fr) | Traitement pour choc hémorragique | |
WO2007127273A3 (fr) | Procédés et compositions permettant de modifier la fonction cellulaire | |
WO2007002836A3 (fr) | Procedes et compositions pour la prevention et le traitement de maladie renale | |
WO2005007078A3 (fr) | Methodes d'inhibition du metapneumovirus humain et du coronavirus humain dans la prevention et le traitement du sras | |
WO2003103662A3 (fr) | Inhibiteurs de la glycoproteine vi | |
WO2005018605A3 (fr) | Nouvelle formulation | |
WO2007051785A3 (fr) | Utilisation de sdf-1 pour le traitement et/ou la prevention de maladies neurologiques | |
WO2007014943A3 (fr) | Traitement pour maladies neurologiques | |
UA86399C2 (ru) | Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза | |
NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
WO2006131651A3 (fr) | Composition a base d'une avermectine et d’ηydrocortisone notamment pour le traitement de la rosacée | |
EP1262197A3 (fr) | Combinaison thérapeutique pour traiter les troubles du sommeil, y compris l'apnée du sommeil | |
WO2006002846A3 (fr) | Nouveaux analogues de nitrobenzylthioinosine | |
UA95780C2 (en) | Xanthine derivatives as selective hm74a agonists | |
UA95299C2 (ru) | Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с | |
WO2006091222A3 (fr) | Methodes de traitement et de prevention du syndrome respiratoire aigu severe (sars) au moyen de avr118 | |
WO2008043570A8 (fr) | Composés de soutien de l'interféron de type i |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051128 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL HR LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/11 20060101ALI20061011BHEP Ipc: A61K 31/07 20060101ALI20061011BHEP Ipc: C07H 21/04 20060101ALI20061011BHEP Ipc: A01N 43/04 20060101ALI20061011BHEP Ipc: C12Q 1/68 20060101AFI20051202BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070122 |
|
R17C | First examination report despatched (corrected) |
Effective date: 20070625 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080108 |